Stockscreener 앱 받기
4.79
3.23%
-0.16
시간 외 거래:
4.79
전일 마감가:
$4.95
열려 있는:
$4.85
하루 거래량:
578.53K
Relative Volume:
1.32
시가총액:
$294.63M
수익:
-
순이익/손실:
$-130.41M
주가수익비율:
-2.1384
EPS:
-2.24
순현금흐름:
$-67.76M
1주 성능:
-15.52%
1개월 성능:
+3.90%
6개월 성능:
-28.08%
1년 성능:
+9.61%
1일 변동 폭
$4.78
$4.97
1주일 범위
$4.78
$5.774
52주 변동 폭
$3.5001
$12.40
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
명칭
Monte Rosa Therapeutics Inc
전화
617-949-2643
주소
321 HARRISON AVENUE, BOSTON
GLUE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
4.79 | 304.47M | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | 개시 | Wedbush | Outperform |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | 개시 | UBS | Buy |
| 2022-08-15 | 개시 | Jefferies | Buy |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-10-14 | 개시 | SVB Leerink | Mkt Perform |
모두보기
Monte Rosa Therapeutics Inc 주식(GLUE)의 최신 뉴스
What are Monte Rosa Therapeutics Inc. company’s key revenue driversUnlock exclusive stock market forecasts - jammulinksnews.com
Statistical indicators supporting Monte Rosa Therapeutics Inc.’s strengthProfitable Trading Blueprint with Entry Zones - Newser
Options Data Show Bullish Bias in Monte Rosa Therapeutics Inc.Pattern Detection for Entry Confirmation Enabled - metal.it
Sector ETF performance correlation with Monte Rosa Therapeutics Inc.Price Movement and Market Sentiment Analysis - Newser
GLUE’s Stock Market Adventure: 19.49% YTD Growth Amidst Volatility - investchronicle.com
Will Monte Rosa Therapeutics Inc. bounce back from current supportFree Chart Breakout Buy Signal Detection - Newser
How to integrate Monte Rosa Therapeutics Inc. into portfolio analysis toolsEarnings Based Stock Performance Forecast - Newser
What makes Monte Rosa Therapeutics Inc. stock price move sharplyLow Risk High Return Opportunities Identified - metal.it
Real time scanner hits for Monte Rosa Therapeutics Inc. explainedBuy Signal System Based on Price Action - Newser
Monte Rosa Therapeutics Inc. Rebound Backed by Sentiment Shift - metal.it
How does Monte Rosa Therapeutics Inc. generate profit in a changing economyFree Stock Recommendation With Proven Results - jammulinksnews.com
Can Monte Rosa Therapeutics Inc. Regain Lost Ground This QuarterLow Risk High Return Opportunities Identified - metal.it
Monte Rosa Therapeutics Inc. Company Revenue and Profit Trends: A Deep DiveShort Term Risk Controlled Alerts - metal.it
Should you hold or exit Monte Rosa Therapeutics Inc. nowMonthly Long-Term Market Recap and Summary - Newser
Sector ETF performance correlation with Monte Rosa Therapeutics Inc. Daily Entry Opportunity Forecasting Tool - Newser
Monte Rosa Therapeutics Inc. Enters Reversal Setup in Weekly ChartsReal-Time Market Sentiment Tracking Gains Momentum - beatles.ru
Real time scanner hits for Monte Rosa Therapeutics Inc. explained Chart Pattern Recognition for Profit Timing - Newser
What institutional investors are buying Monte Rosa Therapeutics Inc. stockConsistent wealth multiplication - jammulinksnews.com
Is Monte Rosa Therapeutics Inc. a Top Dividend Stock to Watch in 2025Consistent Win Signals - metal.it
Why Monte Rosa Therapeutics Inc. stock attracts strong analyst attention Free Accurate Buy Point for Momentum Stocks - Newser
What are the technical indicators suggesting about Monte Rosa Therapeutics Inc.Consistent high-yield stocks - jammulinksnews.com
What are the latest earnings results for Monte Rosa Therapeutics Inc.High-return market picks - jammulinksnews.com
How strong is Monte Rosa Therapeutics Inc. company’s balance sheetRemarkably fast returns - jammulinksnews.com
Why Monte Rosa Therapeutics Inc. stock attracts strong analyst attentionFree Financial Group - Newser
How Monte Rosa Therapeutics Inc. stock performs during market volatilityFree Access to Community - Newser
What analysts say about Monte Rosa Therapeutics Inc. stockOverwhelming profit margins - Autocar Professional
What drives Monte Rosa Therapeutics Inc. stock priceFree Trend-Following Techniques - Autocar Professional
Is Monte Rosa Therapeutics Inc. a good long term investmentFree Trading Strategy Suggestions - Autocar Professional
Monte Rosa Therapeutics Inc. Stock Analysis and ForecastPhenomenal wealth increase - jammulinksnews.com
Monte Rosa Therapeutics Announces First Subjects Dosed in - GlobeNewswire
Monte Rosa Therapeutics and the Breakthrough Potential of MRT-8102 in Inflammatory Disease Treatment - AInvest
Monte Rosa begins phase 1 trial of NEK7-targeting molecular glue degrader - Investing.com
Monte Rosa Therapeutics Inc (GLUE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Monte Rosa Therapeutics Inc 주식 (GLUE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Leo Chandra P. | Director |
Mar 24 '25 |
Buy |
5.84 |
10,000 |
58,383 |
10,000 |
| Versant Venture Capital VI, L. | 10% Owner |
Oct 28 '24 |
Sale |
9.66 |
89,990 |
869,240 |
2,007,948 |
| Versant Venture Capital VI, L. | 10% Owner |
Oct 29 '24 |
Sale |
9.16 |
67,905 |
621,801 |
1,573,453 |
0.93%
0.15%
자본화:
|
볼륨(24시간):